CAR-T– tag –
-
Vector BioMed Proposes Platform to Accelerate CAR-T Therapy Development from Gene Sequence to Clinic-Ready in Under 12 Months
Vector BioMed USA Overview Vector BioMed is advocating for a platform capable of accelerating CAR-T therapy development from gene sequencing to clinic-ready in under 12 months. This platform aims to reduce therapy costs by adopting a tra... -
Imunopharm Files for Shanghai STAR Market IPO, Targeting $550 Million Valuation to Expand CAR-T and CDMO Business
VCBeat China Overview Chinese biotechnology firm Imunopharm has filed for an Initial Public Offering (IPO) on the Shanghai STAR Market, targeting a valuation of 4 billion RMB (approximately $550 million). The company's pipeline includes ... -
ICR Unveils New ‘DOSET’ Statistical Approach to Optimize Early-Stage Cancer Clinical Trials for CAR-T and Advanced Therapies
The Institute of Cancer Research, London UK Overview Researchers at The Institute of Cancer Research (ICR), London, have developed 'DOSET' (Dose Optimization with Simultaneous Efficacy and Toxicity), a new statistical approach to identif... -
Hospital Capacity, Not Just Manufacturing, Identified as True Bottleneck for CAR-T Therapy Commercialization
Chivanta Unknown Overview The greatest challenge in commercializing CAR-T cell therapies is not solely manufacturing capacity but also the hospital infrastructure and the overall treatment process. Clinical operational bottlenecks, speci... -
Fate Therapeutics Receives FDA IND Approval for CAR-T Therapy FT839 for Autoimmune Diseases, Advancing to Phase 1/2 Clinical Trial
GlobeNewswire USA Overview Fate Therapeutics has received U.S. FDA Investigational New Drug (IND) approval for its CAR-T cell therapy candidate, FT839, targeting autoimmune diseases. The company plans to initiate a Phase 1/2 basket clini... -
Curocell’s Rimqarto, South Korea’s First Homegrown CAR-T, Clears Initial Hurdle for National Health Insurance Reimbursement
KBR (Korea Biomedical Review) South Korea Overview Curocell's Rimqarto (anbalcabtagene autoleucel), South Korea's first domestically developed CAR-T cell therapy, has successfully cleared its initial major step towards national health in... -
Dual-Target CAR T Therapy for Glioblastoma Drives Broad Immune Activation, NK Cell Response Correlates with Long-Term Survival in Penn Medicine Study
Vertex AI Search USA Overview Researchers at the Perelman School of Medicine and Abramson Cancer Center discovered that direct intra-cerebrospinal fluid (CSF) delivery of a dual-target CAR T-cell therapy induces a broad immune response i... -
Unicorn Bioscience Report Projects Regenerative Medicine Market to Reach $58.4 Billion in 2026, Scaling to $360 Billion by 2034
Unicorn Bioscience USA Overview Unicorn Bioscience has published a market research report projecting the regenerative medicine market to reach approximately $58.4 billion in 2026, with an anticipated surge to $360 billion by 2034. This g... -
CRISPR Gene Therapies Expand Beyond Initial FDA Approvals, Advancing to Late-Stage Trials for Diverse Indications
Ubie Doctor's Note USA Overview As of mid-2026, two CRISPR gene therapies, Casgevy (for sickle cell disease and beta-thalassemia) and EDIT-101 (for Leber congenital amaurosis type 10), have received FDA approval, establishing foundationa... -
NTHRYS Achieves 40% Cost Reduction in Dual Antigen CAR-T Manufacturing, Offers Off-the-Shelf NK Cell Expansion Services
NTHRYS International Overview NTHRYS has successfully reduced manufacturing costs for dual antigen CAR-T cell scale-up by 40% while accelerating time-to-clinic. Furthermore, the company now offers clinical-grade NK cell expansion and cry...
